Animal study shows significant tumor destruction and improved survival in mice with cancer — Evidence Review
Published in Cancer Cell, by researchers from Icahn School of Medicine at Mount Sinai
Researched by
— the AI search engine for science
Table of Contents
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that targets tumor-associated macrophages rather than cancer cells directly, showing significant survival benefits and complete cures in mouse models of metastatic ovarian and lung cancer. Related research broadly supports the promise of "Trojan horse" and microenvironment-focused cancer therapies, as summarized by the original source.
- Several studies confirm the effectiveness of Trojan horse-inspired strategies, demonstrating that exploiting the tumor microenvironment or immune-modulating mechanisms can enhance delivery and efficacy of cancer treatments, often overcoming barriers faced by conventional therapies 1 2 4 5.
- Research consistently highlights the critical role of tumor-associated macrophages in cancer progression and immune evasion, and recent advances in targeting or reprogramming these cells show that altering the tumor microenvironment can sensitize tumors to immune attack 4.
- Animal models remain essential for preclinical evaluation, with strong evidence supporting their predictive utility for studying metastasis, immunotherapy response, and survival outcomes, though translation to human patients remains a key challenge 6 8 9.
Study Overview and Key Findings
Metastatic solid tumors, such as those in the lung and ovary, are often resistant to existing immunotherapies, largely due to the immune-suppressive environment created by tumor-associated macrophages. The new study seeks to overcome this barrier by engineering CAR T cells to selectively target and deplete these protective macrophages, while simultaneously releasing immune-stimulating molecules to activate the body's natural defenses. This approach shifts the tumor environment from immune-suppressed to immune-active, potentially making previously unresponsive cancers vulnerable to immune attack.
| Property | Value |
|---|---|
| Study Year | 2023 |
| Organization | Icahn School of Medicine at Mount Sinai |
| Journal Name | Cancer Cell |
| Authors | Jaime Mateus-Tique, Ashwitha Lakshmi, Bhavya Singh, Rhea Iyer, Alfonso R. Sánchez-Paulete, Chiara Falcomata, Matthew Lin, Gvantsa Pantsulaia, Alexander Tepper, Trung Nguyen, Angelo Amabile, Gurkan Mollaoglu, Luisanna Pia, Divya Chhamalwan, Jessica Le Berichel, Hunter Potak, Marco Colonna, Alessia Baccarini, Joshua Brody, Miriam Merad, Brian D. Brown |
| Population | Mice with metastatic lung and ovarian cancer |
| Methods | Animal Study |
| Outcome | Tumor environment changes, cancer cell destruction |
| Results | Mice lived months longer, many were completely cured. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus paper database, which contains over 200 million scientific papers. We used the following search queries to identify relevant literature:
- Trojan horse cancer therapy effectiveness
- mice cancer treatment survival rates
- cancer therapy complete remission results
Below, we summarize key themes and findings from related studies:
| Topic | Key Findings |
|---|---|
| How do "Trojan horse" strategies improve cancer therapy? | - Trojan horse nanotechnology and biomimetic systems enhance drug delivery, tumor penetration, and cytotoxicity, sometimes achieving complete cures in animal models 2 3 5. - Modulating the tumor microenvironment or using immune-stimulatory strategies can increase the efficacy of such approaches 1 4 5. |
| What is the role of tumor-associated macrophages and the microenvironment in therapy resistance? | - Tumor-associated macrophages (TAMs) support cancer immune evasion and metastasis; therapies that reprogram or deplete TAMs can restore immune activity and sensitize tumors to immunotherapy 4. - Shifting the tumor milieu from immune-suppressive ("cold") to immune-active ("hot") correlates with improved outcomes 4 7. |
| How well do mouse models predict outcomes for metastatic and refractory cancer therapies? | - Advanced mouse models can recapitulate human tumor behavior, including metastasis and therapy resistance, providing essential platforms for preclinical evaluation 6 8 9. - Combination and multimodal therapies in mice can significantly prolong survival and achieve complete remission in some cases 9 10 12. |
| What are the rates and predictors of complete remission in cancer therapy? | - Complete remission rates vary by cancer type and treatment; molecular targeting and immunotherapies can induce high remission rates in some hematologic cancers but remain challenging in solid tumors 11 12 13 14. - Consolidation strategies and microenvironment targeting may improve remission durability 11 14 15. |
How do "Trojan horse" strategies improve cancer therapy?
Recent research demonstrates that Trojan horse-inspired therapies, which use disguised or hijacked delivery mechanisms, can overcome biological barriers to drug delivery, achieve targeted tumor penetration, and maximize cytotoxic effects. These approaches range from nanoparticles that change form within the tumor microenvironment to biomimetic cell membrane-coated agents for precise delivery 2 3 5. The new study builds on this foundation by using engineered immune cells to gain entry into the tumor via its own defensive cells, further enhancing the Trojan horse concept.
- Trojan horse nanoparticles and biomimetic constructs have shown high internalization and potent cytotoxicity in cancer cells, sometimes resulting in complete cures in animal models 2 3 5.
- These delivery systems can integrate diagnostic and therapeutic functions, facilitating precision treatment and monitoring 2 5.
- Modifying the tumor microenvironment, such as by releasing immune stimulators or targeting immune-suppressive cells, can further enhance the efficacy of Trojan horse therapies 1 4.
- The new study's macrophage-targeting approach represents an evolution of these strategies, leveraging immune engineering to reprogram the tumor environment from within 4.
What is the role of tumor-associated macrophages and the microenvironment in therapy resistance?
Tumor-associated macrophages (TAMs) are recognized as major contributors to immune suppression and tumor progression. Strategies that reprogram TAMs from a pro-tumor ("M2-like") to an anti-tumor ("M1-like") phenotype, or that selectively deplete them, can convert immunologically "cold" tumors into "hot" tumors, making them more responsive to immunotherapies 4. The current study's focus on TAMs aligns with this trend, supporting the notion that targeting the tumor microenvironment is a promising approach to overcoming resistance in solid cancers.
- TAMs facilitate cancer growth by suppressing cytotoxic immune responses and promoting metastasis 4.
- Therapies that block macrophage checkpoints (e.g., CD47) or deliver immune-activating agents through Trojan horse mechanisms can reshape the tumor microenvironment and restore immune function 4 5.
- Successful reprogramming or removal of TAMs has been shown to inhibit tumor growth and enhance the effects of other immunotherapies 4.
- The new CAR T cell therapy's antigen-independent mechanism could broaden its applicability by bypassing the need for specific tumor cell markers 4.
How well do mouse models predict outcomes for metastatic and refractory cancer therapies?
Animal models, particularly advanced mouse models, are crucial for preclinical testing of cancer therapies. They can mimic human tumor growth, metastasis, and response to treatment, providing valuable insights into therapeutic efficacy and safety before human trials 6 8 9. While there are limitations in translation, studies show that combination and multimodal therapies can significantly extend survival and increase the rate of complete remission in animal models, as observed in the new study 9 10 12.
- Mouse models, including orthotopic and genetically engineered systems, closely reflect human disease patterns, especially for testing treatment of metastasis and chemoresistance 6 8.
- Multimodal and combination therapies in mice have led to improved survival and, in some cases, complete remission, supporting the relevance of such models for preclinical research 9 10 12.
- The new study’s observation of long-term survival and cures in mice aligns with previous successful preclinical therapies, though clinical translation remains to be established 8 9.
- Limitations include species differences and variable immunological responses, highlighting the need for further validation in human studies 6.
What are the rates and predictors of complete remission in cancer therapy?
Complete remission (CR) is a major therapeutic goal, but rates vary widely depending on cancer type and therapy. Molecularly targeted and immune-based treatments have achieved high remission rates in hematologic malignancies, but durable CR in solid tumors remains rare 11 12 13 14. The new study's success in curing mice with metastatic solid tumors is notable, suggesting that targeting the tumor microenvironment could enhance remission rates and durability in otherwise resistant cancers.
- Long-term complete remissions are rare in metastatic solid cancers treated with standard chemotherapy, underscoring the need for novel consolidation and maintenance strategies 11 14.
- CAR T cell therapies and other immune-targeted approaches have shown the ability to induce rapid and deep remissions, especially in leukemias and lymphomas 12 13.
- Comprehensive genomic profiling and microenvironment modulation may further improve remission rates and outcomes, particularly in refractory cases 14 15.
- The findings from the new study suggest that targeting support cells in the tumor microenvironment could be an effective avenue for increasing CR rates in solid tumors, warranting further investigation 4.
Future Research Questions
While the new study presents promising preclinical results, significant questions remain regarding safety, efficacy, and translational potential. Further research is needed to determine optimal strategies for targeting tumor-associated macrophages, the long-term effects of such therapies, and their applicability across diverse cancer types. Addressing these questions will help clarify the potential for microenvironment-targeted immunotherapies to improve outcomes where current options fall short.
| Research Question | Relevance |
|---|---|
| What are the long-term effects and safety profile of macrophage-targeted CAR T cell therapies in humans? | Understanding safety and potential off-target effects in humans is critical before clinical translation, as animal studies do not always predict human toxicities or immune responses 6 8. |
| Can macrophage-targeted immunotherapy be combined with other modalities to improve remission durability in solid tumors? | Combination therapies have shown synergistic effects in preclinical models; exploring combinations could enhance durability and breadth of response in resistant tumor types 9 10 14 15. |
| How does tumor microenvironment heterogeneity impact the efficacy of antigen-independent immunotherapies? | Tumor heterogeneity may affect therapy outcomes; understanding these effects is important for predicting which patients may benefit from macrophage-targeted treatments 4 6 15. |
| What are the mechanisms of resistance to macrophage-depleting therapies in solid cancers? | Identifying resistance pathways will guide future therapy development and help in designing strategies to overcome or prevent resistance 4 15. |
| Can macrophage-targeted CAR T cell therapies be adapted for other tumor types beyond lung and ovarian cancer? | Macrophages are present in many tumor types; determining the therapy’s applicability and efficacy across diverse cancers could broaden its clinical impact 4 6. |